国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
1期
64-67
,共4页
陈旭东%孙金林%解现金%王言森
陳旭東%孫金林%解現金%王言森
진욱동%손금림%해현금%왕언삼
阿托伐他汀%川芎嗪注射液%慢性阻塞性肺疾病
阿託伐他汀%川芎嗪註射液%慢性阻塞性肺疾病
아탁벌타정%천궁진주사액%만성조새성폐질병
Atorvastatin%Ligustrazine injection%Chronic obstructive pulmonary disease (COPD)
目的 探讨阿托伐他汀联合川芎嗪注射液治疗慢性阻塞性肺疾病(COPD)加重期的临床疗效.方法 选择86例COPD急性加重期兼瘀血症患者,随机分为观察组和对照组,各43例,对照组采用常规治疗加阿托伐他汀,观察组在对照组基础上用川芎嗪注射液,观察两组患者血清白介素(IL)-6、IL-8、肿瘤坏死因子(TNF-α)水平及肺功能指标的改变情况及临床疗效.结果 治疗后6个月,观察组IL-6、IL-8、TNF-α水平分别为(27.3-3.6) ng/L、(1.3±0.3) ng/L、(16.9±3.4)ng/L,明显低于对照组[(33.9±3.4)ng/L、(1.6±0.2)ng/L、(23.1±3.9)ng/L](P＜0.05);观察组FVC、FEV1、FEV 1/FVC分别为(2.6±0.2)L、(1.3±0.3)L、(88.5±9.8)％,改善程度明显优于对照组[(2.4±0.2)L、(1.5±0.4)L、(83.2±9.3)％](P＜0.05);观察组总有效率为97.7％优于对照组(88.4％);两组无不良反应发生.结论 阿托伐他汀联合川芎嗪注射液治疗痰热阻肺型COPD急性加重期能更有效的控制肺组织炎症反应,改善肺功能,从而提高临床疗效,且安全可靠.
目的 探討阿託伐他汀聯閤川芎嗪註射液治療慢性阻塞性肺疾病(COPD)加重期的臨床療效.方法 選擇86例COPD急性加重期兼瘀血癥患者,隨機分為觀察組和對照組,各43例,對照組採用常規治療加阿託伐他汀,觀察組在對照組基礎上用川芎嗪註射液,觀察兩組患者血清白介素(IL)-6、IL-8、腫瘤壞死因子(TNF-α)水平及肺功能指標的改變情況及臨床療效.結果 治療後6箇月,觀察組IL-6、IL-8、TNF-α水平分彆為(27.3-3.6) ng/L、(1.3±0.3) ng/L、(16.9±3.4)ng/L,明顯低于對照組[(33.9±3.4)ng/L、(1.6±0.2)ng/L、(23.1±3.9)ng/L](P＜0.05);觀察組FVC、FEV1、FEV 1/FVC分彆為(2.6±0.2)L、(1.3±0.3)L、(88.5±9.8)％,改善程度明顯優于對照組[(2.4±0.2)L、(1.5±0.4)L、(83.2±9.3)％](P＜0.05);觀察組總有效率為97.7％優于對照組(88.4％);兩組無不良反應髮生.結論 阿託伐他汀聯閤川芎嗪註射液治療痰熱阻肺型COPD急性加重期能更有效的控製肺組織炎癥反應,改善肺功能,從而提高臨床療效,且安全可靠.
목적 탐토아탁벌타정연합천궁진주사액치료만성조새성폐질병(COPD)가중기적림상료효.방법 선택86례COPD급성가중기겸어혈증환자,수궤분위관찰조화대조조,각43례,대조조채용상규치료가아탁벌타정,관찰조재대조조기출상용천궁진주사액,관찰량조환자혈청백개소(IL)-6、IL-8、종류배사인자(TNF-α)수평급폐공능지표적개변정황급림상료효.결과 치료후6개월,관찰조IL-6、IL-8、TNF-α수평분별위(27.3-3.6) ng/L、(1.3±0.3) ng/L、(16.9±3.4)ng/L,명현저우대조조[(33.9±3.4)ng/L、(1.6±0.2)ng/L、(23.1±3.9)ng/L](P＜0.05);관찰조FVC、FEV1、FEV 1/FVC분별위(2.6±0.2)L、(1.3±0.3)L、(88.5±9.8)％,개선정도명현우우대조조[(2.4±0.2)L、(1.5±0.4)L、(83.2±9.3)％](P＜0.05);관찰조총유효솔위97.7％우우대조조(88.4％);량조무불량반응발생.결론 아탁벌타정연합천궁진주사액치료담열조폐형COPD급성가중기능경유효적공제폐조직염증반응,개선폐공능,종이제고림상료효,차안전가고.
Objective To investigate the clinical efficacy of atorvastatin combined with ligustrazine injection in treating exacerbations of chronic obstructive pulmonary disease (COPD).Methods 86 cases of patients with acute exacerbation of COPD and blood stasis were selected and randomly divided into observation group and control group,with 43 cases in each group,control group was treated with conventional therapy combined with atorvastatin,observation group was treated with ligustrazine injection based on control group,and the clinical efficacy,lung function index and serum IL-6,IL-8,TNF-α levels were observed between two groups.Results After 6 months of treatment,the IL-6,IL-8,TNF-α levels in observation group were (27.3 ± 3.6) ng/L,(1.3 ± 0.3) ng/L and (16.9 ± 3.4) ng/L respectively,significantly lower than those in control group [(33.9 ± 3.4) ng/L,(1.6 ± 0.2) ng/L,(23.1 ± 3.9) ng/L](P ＜ 0.05); the FVC,FEV1,FEV1/FVC (％) in observation group were (2.6 ± 0.2) L,(1.3 ± 0.3) L and (88.5 ± 9.8)％ respectively,improving more significantly than those in control group [(2.4 ± 0.2) L,(1.5 ±-0.4) L,(83.2 ± 9.3)％] (P ＜ 0.05); the total effective rate in observation group was 97.7％,better than that in control group (88.4％); two gronps had no adverse reactions.Conclusion Atorvastatin combined with ligustrazine injection in treating acute exacerbation of COPD and blood stasis can make lung tissue inflammation control more effective,improve lung function,so as to improve clinical efficacy,which provides safety and reliability.
